Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-2.28%||Sales Growth - Q/Q||-2.2%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-31.53%||ROE||-36.59%||ROI|
|Current Ratio||9.89||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.1|
|Gross Margin||Operating Margin||-1592.24%||Net Profit Margin||-1595.01%||Dividend Payout Ratio|
|Cash From Financing Activities||113.04 M||Cash From Investing Activities||9.44 M||Cash From Operating Activities||-47.15 M||Gross Profit|
|Net Profit||-46.91 M||Operating Profit||-46.5 M||Total Assets||486.3 M||Total Current Assets||403.45 M|
|Total Current Liabilities||40.79 M||Total Debt||Total Liabilities||67.32 M||Total Revenue||2.36 M|
|High 52 week||54.86||Low 52 week||18.54||Last close||19.45||Last change||-0.87%|
|RSI||48.69||Average true range||1.55||Beta||1.7||Volume||8.33 M|
|Simple moving average 20 days||-2.38%||Simple moving average 50 days||-14.94%||Simple moving average 200 days||-41.62%|
|Performance Week||-3.71%||Performance Month||-1.12%||Performance Quart||-30.95%||Performance Half||-52.41%|
|Performance Year||-62.06%||Performance Year-to-date||-60.05%||Volatility daily||5.55%||Volatility weekly||12.41%|
|Volatility monthly||25.44%||Volatility yearly||88.11%||Relative Volume||1513.75%||Average Volume||1.45 M|
|New High||New Low|
2019-01-15 08:04:07 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-01-09 08:04:25 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-01-07 08:11:44 | Why Portola Pharmaceuticals Rose 8.09% on January 4
2019-01-03 14:01:01 | Take Profits on This Pharma Stock
2019-01-02 09:25:02 | Portola Up as Large-Scale Andexxa Production Gets FDA Nod
2018-12-31 15:59:00 | Portola stock shoots higher after FDA approval
2018-12-18 08:30:00 | Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019
2018-12-17 14:58:37 | Portola Pharmaceuticals, Inc. NASDAQ:PTLA: Is Breakeven Near?
2018-12-13 16:45:00 | Here's Why Portola Pharmaceuticals Fell 11% Today
2018-12-13 00:07:12 | Is Portola Pharmaceuticals Inc PTLA A Good Stock To Buy?
2018-12-12 10:15:03 | Portola PTLA Down as CHMP Defers Review Date for Ondexxya
2018-12-11 14:04:05 | Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
2018-12-11 11:13:00 | Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding
2018-12-11 07:00:00 | CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ andexanet alfa
2018-12-04 07:30:00 | Recent Analysis Shows Portola Pharmaceuticals, Xenia Hotels & Resorts, WestRock, Newtek Business Services, The ExOne, and VMware Market Influences — Renewed Outlook, Key Drivers of Growth
2018-12-03 21:15:00 | Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
2018-11-24 08:05:16 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2018-11-15 08:04:27 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2018-11-09 10:21:28 | Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
2018-11-09 09:16:00 | Here's What Portola Pharmaceuticals Is Saying About Its Future
2018-11-07 23:31:10 | Edited Transcript of PTLA earnings conference call or presentation 7-Nov-18 9:30pm GMT
2018-11-07 19:30:12 | Portola Pharmaceuticals PTLA Reports Q3 Loss, Tops Revenue Estimates
2018-11-07 18:26:26 | Portola Pharmaceuticals: 3Q Earnings Snapshot
2018-11-06 16:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2018-11-06 08:05:10 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2018-11-01 17:30:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2018-10-27 08:06:17 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2018-10-25 08:25:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Portola Pharmaceuticals, Cable One, Marriot Vacations Worldwide, United Technologies, Park-Ohio, and BioScrip — New Research Emphasizes Economic Growth
2018-10-11 15:36:00 | Why Portola Pharmaceuticals Stock Shed 11% in September
2018-10-09 15:44:02 | What You Must Know About Portola Pharmaceuticals Inc’s NASDAQ:PTLA Market Risks
2018-10-08 17:35:02 | Recent Developments for Portola Pharmaceuticals
2018-10-08 16:05:08 | A Look at Portola Pharmaceuticals’ Financial Performance
2018-10-08 14:34:17 | Analysts Are Mostly Positive on Portola Pharmaceuticals
2018-09-26 11:14:03 | Portola's PTLA Lymphoma Candidate Gets Orphan Drug Status
2018-09-26 07:31:27 | Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto
2018-09-24 11:10:31 | Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms
2018-09-20 08:30:00 | Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer
2018-09-11 14:07:00 | Here's Why Portola Pharmaceuticals, Inc. Fell 16.6% in August
2018-09-07 08:30:00 | Portola Pharmaceuticals Announces Executive Leadership Change
2018-09-07 08:18:00 | 3 Top Biotech Stocks to Buy in September
2018-09-05 18:15:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4